Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis. J of Skin. 2017;1(3.1):s12. doi:10.25251/skin.1.supp.11